⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IBRX News
ImmunityBio, Inc. Common Stock
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
prnewswire.com
IBRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
accessnewswire.com
IBRX
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
prnewswire.com
ACRV
BNTX
IBRX
ONCY
MAIA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
globenewswire.com
IBRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
accessnewswire.com
IBRX
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA ® Plus CAR-NK, Chemo-Free Therapy
businesswire.com
IBRX
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA ® in BCG-Unresponsive Papillary Bladder Cancer
businesswire.com
IBRX
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
prnewswire.com
GTBP
IBRX
ERAS
CHRS
NBP
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
businesswire.com
IBRX
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
businesswire.com
IBRX